Article
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Nature medicine - 1 Mar 2023
Mellinghoff Ingo K, Lu Min, Wen Patrick Y, Taylor Jennie W, Maher Elizabeth A, Arrillaga-Romany Isabel, Peters Katherine B, Ellingson Benjamin M, Rosenblum Marc K, Chun Saewon, Le Kha, Tassinari Ania, Choe Sung, Toubouti Youssef, Schoenfeld Steven, Pandya Shuchi S, Hassan Islam, Steelman Lori, Clarke Jennifer L, Cloughesy Timothy F
Abstract excerpt
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase 1 trial to explore the mechanism of action in recurrent low-grade glioma (IGG) and select a molecule for phase 3 testing. Primary end-point was concentration of D-2-hydroxyglutarate (2-HG), the metabolic product of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.